McKew John C.

Chief Scientific OfficerLUMOS PHARMA, INC. ((LUMO)) · full profile →Form 4 · filed Dec 13, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
9
1 non-derivative · 8 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 12, 2024Disposed to issuer(D)13K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 12, 2024Disposed to issuer(D)16K0
Dec 12, 2024Disposed to issuer(D)33K0
Dec 12, 2024Disposed to issuer(D)14K0
Dec 12, 2024Disposed to issuer(D)65K0
Dec 12, 2024Disposed to issuer(D)82K0
Dec 12, 2024Disposed to issuer(D)10K0
Dec 12, 2024Disposed to issuer(D)7K0
Dec 12, 2024Disposed to issuer(D)16K0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001126234-24-000120) within minutes of acceptance. Every field above traces to the original document. Verify it directly: